This webinar discusses the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Assays that measure a single type of biomarker – such as mutational burden assays – are important, but can be misleading for informing cancer immunotherapy treatment selection. Comprehensive immune profiling strategies that incorporate standard biomarkers alongside RNA-seq can be more informative, based upon the hypothesis that overexpression of an immune marker should correlate with therapeutic benefit as in the case of HER2 and Herceptin.

This comprehensive immune profiling approach could potentially impact as many as half of patients who are not PD-L1 IHC positive (tumor proportion score of 50%) or mutational burden high.

This webinar includes insights from the OmniSeq reference population, a review of comprehensive immune profiles from clinical cases at UC San Diego, and implications for immunotherapy from LabCorp.